Osteo-Pharma announces Scientific Advisory Board June 21, 2016
Osteo-Pharma, a Dutch Life Sciences company developing novel pharmaceuticals and medical devices to improve the local healing of bone fractures and defects, announced its Scientific Advisory Board (SAB) comprising experts in the field of bone and dental regenerative biology from the U.S. and Europe.
The Company anticipates that the SAB will address a variety of novel issues at the forefront of local bone regeneration, including evaluations of new discoveries in basic and applied regenerative biology, the growing interest in the field in local and sustained drug delivery, clinical trial priorities and designs and related matters.
The SAB members include the following:
Pr. Roland Baron
Pr. Roland Baron is professor at the Harvard Medical School, Endocrine Unit, Massachusetts General Hospital, and chair of Oral Medicine at the Harvard School of Dental Medicine from January 2008. From 1977 to 2007, Pr. Roland Baron was a professor in the departments of Orthopaedics and Cell Biology at Yale University School of Medicine. He received his DDS and PhD degrees from the University of Paris Medical School, France. He is the founder and past Editor-in-Chief of BONE. Dr Baron was the President of the American Society for Bone and Mineral Research 2014-2015. Between 1994 and 2002, he also held the position of vice-president and head of the Bone Diseases Group at Hoechst Marion Roussel and then Aventis. In 2002 he founded ProSkelia, a small pharmaceutical company devoted to the discovery and development of new drugs for bone and hormonal dependent diseases. He has held the positions of President and chief scientific officer of ProSkelia and then ProStrakan, until April 2006. Pr. Baron has published over 330 scientific papers in the field of bone biology and bone diseases.
Pr. Martijn van Griensven
Pr. Martijn van Griensven (1974) was trained as a general surgeon and as an orthopaedic trauma surgeon in Hannover (D). He was appointed as full professor for experimental trauma surgery in 2000. In 2005, he became co-director of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in Vienna, Austria. In September 2011, he was appointed as director for the department of Experimental Trauma Surgery at the Technical University Munich, Germany. His research areas are related to engineering methods for the musculoskeletal system using stem cells of different sources, biomaterials, gene therapy and mechanical loading. His most recent grants deal with engineering the enthesis (ligament-to-bone transition), oxygen measurement in scaffolds and also with miRNA usage for diagnostics and therapeutics. He has published 248 peer reviewed original papers, 20 book chapters and he has edited 4 books. He has received several awards for his work, among others the young scientist award from the World Biomaterials Society.
Pr. John Jansen
Pr. John Jansen is a professor in biomaterials, experimental implantology and experimental periodontology and is the Head of the Department of Biomaterials of the College of Dental Sciences of the Radboud university medical center, Nijmegen, the Netherlands. He received his DDS and PhD degrees form the Radboud University, Nijmegen, The Netherlands and was employed at the Free University, Amsterdam and Leiden university, Leiden, The Netherlands before he returned to the Radboud University in 1992. Moreover, he received numerous awards, like the Simon Stevin Mastership award of the Dutch Technology Foundation, Clemson award for Outstanding Contributions to the literature of the Society for Biomaterials, FEDERA award of the Federation of Dutch Medical Scientific Societies, Isaac Schour Memorial award of the International Organization for Dental Research. He is member of the Royal Netherlands Academy of Arts and Sciences as well as Academia European. He is also the co-editor-in-chief of the Journal Tissue Engineering Part C. His research focuses on the analysis and development of new biomaterials for use as dental/orthopaedic implants, bone substitutes and scaffolds for tissue engineering. He published more than 650 publications in international journals.
Osteo-Pharma is a Life Sciences company focused on the development of local treatments to improve the healing of bone fracture and defects. It’s proprietary OsteoActivator platform is used to develop biodegradable films, microspheres and coatings for implants with sustained release of small molecule drugs that enhance bone formation while simultaneously inhibiting bone resorption. The company is currently in mid-late stage pre-clinical development with various projects and anticipates to initiate the first human clinical trials in the course of 2017/2018.
Osteo-Pharma receives up to € 2 Million Innovation Credit from Dutch Government
Oss, The Netherlands – June 16, 2016 – Osteo-Pharma BV, a Life Sciences company focusing on the development of local treatments to improve the healing of bone fractures and defects, announces today that it has received an innovation credit of up to € 2 million from the Rijksdienst voor Ondernemers (RVO), an agency executing programs for the Dutch Ministry of Economic Affairs, Agriculture and Innovation. The innovation credit will be applied to support the development of Osteo-Pharma’s lead product OP-001 for local bone healing. Under the terms of the agreement, Osteo-Pharma receives up to € 2,098,239 to support pre-clinical and clinical stages of the project. The credit will become repayable subject to the commercial success of the project. “We are delighted to receive the Innovation Credit for our lead program, as these funds are only provided to innovative projects with strong commercial prospects,” said Jan Gossen, Chief Executive Officer of Osteo-Pharma. “This credit will allow us, upon successful pre-clinical studies, to take OP001 into clinical development for treatment of bone fractures”. OP001 is a novel combination product to enhance the healing of bone fractures and defects. The project is currently in late stage pre-clinical stages.
Osteo-Pharma is a Life Sciences company focused on the development of local treatments to improve the healing of bone fracture and defects. It’s proprietary OsteoActivator platform is used to develop biodegradable films, microspheres and coatings for implants with sustained release of small molecule drugs that enhance bone formation while simultaneously inhibiting bone resorption. The company is currently in mid-late stage pre-clinical development with various projects and anticipates to initiate the first human clinical trials in the course of 2017.
For more information, please contact:
Jan Gossen CEO